Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hypertension and diabetes.

Karin Jandeleit-Dahm1, Mark E Cooper

  • 1Department of Medicine, Repatriation Hospital, West Heidelberg, Victoria, Australia.

Current Opinion in Nephrology and Hypertension
|February 22, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mitochondrial Alterations and CKD.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2026
Same author

Resolving the VEGF paradox in DKD: VEGFR1 blockade shows promising renoprotection.

Kidney international·2026
Same author

EZH2 inhibition via GSK-126 mitigates EndMT and atherosclerosis in diabetes: A translational epigenetic approach.

Science advances·2026
Same author

Effects of empagliflozin on cardiac function and cardiorespiratory fitness in people with type 2 diabetes: a randomised controlled trial.

Cardiovascular diabetology. Endocrinology reports·2026
Same author

Technological Innovations and the Translational Path of Kidney Organoids.

Biomedicines·2026
Same author

Epigenetic Regulation of VCAM-1 by Lipoxin A4 Is Renoprotective Against Diabetic Kidney Disease.

Diabetes·2026
Same journal

Updates in management of cardiorenal syndrome.

Current opinion in nephrology and hypertension·2026
Same journal

Sex differences in renal acid-base regulation.

Current opinion in nephrology and hypertension·2026
Same journal

Primary prevention of chronic kidney disease in type 2 diabetes mellitus with sodium-glucose cotransporter 2 inhibitors.

Current opinion in nephrology and hypertension·2026
Same journal

Financial and policy challenges of delivering kidney replacement therapies in resource-limited settings.

Current opinion in nephrology and hypertension·2026
Same journal

The role of kir4.1/Kir5.1 in mediating the effect of angiotensin-II on Na-Cl-cotransporter.

Current opinion in nephrology and hypertension·2026
Same journal

Role of the calcium-sensing receptor in regulating calcium transport in the thick ascending limb.

Current opinion in nephrology and hypertension·2026
See all related articles

Hypertension accelerates diabetes complications, particularly kidney disease. Renin-angiotensin system inhibitors offer kidney protection for diabetic patients, with ongoing research into aggressive blood pressure management for vascular health.

Area of Science:

  • Nephrology
  • Cardiology
  • Endocrinology

Background:

  • Hypertension frequently co-exists with diabetes, contributing to insulin resistance and renal disease.
  • High blood pressure exacerbates microvascular and macrovascular complications in diabetic individuals.
  • Vascular and cardiac issues in diabetes, such as atherosclerosis and left ventricular hypertrophy, are worsened by hypertension.

Purpose of the Study:

  • To review the role of hypertension in diabetes progression.
  • To highlight the renoprotective effects of renin-angiotensin system inhibitors in diabetic nephropathy.
  • To discuss ongoing research into aggressive antihypertensive strategies for macrovascular disease in diabetes.

Main Methods:

  • Review of clinical trials and published literature on hypertension and diabetes.

Related Experiment Videos

  • Analysis of hemodynamic and nonhemodynamic mechanisms of renoprotection.
  • Examination of studies investigating aggressive antihypertensive treatments in diabetic populations.

    • Main Results:

    • Renin-angiotensin system inhibitors demonstrate renoprotection in type 1 and type 2 diabetes with varying stages of renal disease.
    • These agents offer benefits through multiple mechanisms, including hemodynamic and nonhemodynamic pathways.
    • Evidence suggests hypertension accelerates cardiovascular abnormalities in diabetes.

    Conclusions:

    • Agents targeting the renin-angiotensin system are crucial for renoprotection in diabetic patients.
    • Aggressive blood pressure management is an area of active investigation for mitigating macrovascular risks in diabetes.
    • Understanding the interplay between hypertension and diabetes is vital for comprehensive patient care.